H.C. Wainwright initiated coverage of Acelyrin with a Buy rating and $44 price target. The company’s pipeline of assets with “de-risked targets” offers features which could potentially improve on efficacy and/or safety compared to drugs approved or in development in their respective drug classes, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SLRN:
- Billionaire Ken Griffin Pours Millions Into These 2 ‘Strong Buy’ Stocks — Here’s Why You Might Want to Ride His Coattails
- Acelyrin reports Q2 EPS (40c), consensus (81c)
- ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
- ACELYRIN, INC. to Present Second Quarter 2023 Financial Results and Corporate Update on August 14, 2023
- Acelyrin management to meet virtually with Piper Sandler